Bipolarity studies

Activa’t per la salut mental! / “Get active!: Increase active participation of people with mental disorders and their families in their recovery processes”

This study isn't currently recruiting.

Countries

Spain

Sponsor

Catalan Federation of Mental Health (Federació Salut Mental Cataluny)

Brief exercise for depressive and anxiety symptoms among inpatients with severe mental illness

This study isn't currently recruiting.

Countries

Malaysia

Sponsor

University Kebangsaan Malaysia Medical Centre

Contingency intervention for reduction of cannabis in early psychosis

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

University College London (UK)

How genetics, behaviour, and environment can contribute to a condition called metabolic syndrome in people who are taking antipsychotic medication

This study isn't currently recruiting.

Countries

Italy

Sponsor

Ministero della Salute

Mobile technology health management for people with severe mental illness

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

East London NHS Foundation Trust

Comparison of bifrontal and unilateral ultrabrief pulse electroconvulsive therapy in major depression

This study isn't currently recruiting.

Countries

Belgium

Sponsor

Catholic University Leuven (Belgium)

Testing an intervention to promote good oral health in people with severe mental illness

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

Sheffield Health and Social Care NHS Foundation Trust

A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

AstraZeneca AB

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Bulgaria, Spain

Sponsor

Cephalon, Inc.

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Finland, Germany, + 3 others

Sponsor

Cephalon, Inc.

A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia...

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Hungary, Poland

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing Trial A7501008 and Continuing Lithium or Valproic Acid/Divalp...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Czechia

Sponsor

N V Organon